Moreover, as part of routine clinical practice, monitoring changes in plasma NfL levels alongside other ATN biomarkers could offer insights into disease trajectory and treatment efficacy, allowing for timely adjustments to therapeutic approaches. This evidence concerns the gene NEFL and oculocutaneous albinism type 1.